Braveheart Bio starts Phase 3 oHCM trial, reports Q2 2026 resultsSep 8Quarterly updateBraveheart Bio, Inc.
Cytokinetics reports positive ACACIA-HCM results for aficamten in non-obstructive HCMAug 28Clinical readoutaficamtenCytokinetics
Cytokinetics reports Q2 2026 results, ACACIA-HCM hits both primary endpointsAug 6Quarterly updateaficamtenCytokinetics
Braveheart Bio files for IPO, plans two global Phase 3 trials for HCM drug BHB-1893Jul 14FinancingBHB-1893Braveheart Bio, Inc.
Sign inSign in